Genetic engineering is giving a new meaning to the term "manufacturing plant" as the biotechnology industry looks to potatoes, corn, tobacco, and other crops to provide cheap manufacturing sources for therapeutic The lack of capacity for the cost-effective manufacture of protein-based pharmaceuticals will soon cause a significant bottleneck at pharmaceutical companies, one that threatens to impede the progress of therapeutics at all stages of development, from the preclinical stage to commercialization. Today, companies are faced with the limited options of either queuing up for outsourced manufacturing, or investing hundreds of millions of dollars in their own production capacity well before they know that a product will succeed. A bumper crop of new companies is therefore poised to take advantage of the manufacturing capabilities of plants that have been genetically engineered to produce human proteins.
Genetic engineering is giving a new meaning to the term
"manufacturing plant" as the biotechnology industry looks to
potatoes, corn, tobacco, and other crops to provide cheap
manufacturing sources for therapeutic proteins.
The lack of capacity for the cost-effective manufacture of protein-based pharmaceuticals will soon cause a significant bottleneck at pharmaceutical companies,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
